I get your perspective on the Prostate Test. It solves all financial issues if it can roll out as you say. My intel says not that simple and not as likely as Pestell is painting it. I’m not going to get into all the details but basically there is considerable expense to monetize the Prostate test and valuations are not realistic.
This is not my area of expertise so I’m just repeating what I am hearing. Mono is much further down the clinical path and it could be sold off separately with royalties on the Cancer indications being another package - with Pestell possibly finding a new home with whoever buys the molecule.
We will know so much more 1H 2019. I can’t imagine being out of this stock for even one day at this point.
News 
Market Data 
Discover 
